Email updates

Keep up to date with the latest news and content from Journal of Ovarian Research and BioMed Central.

Open Access Research

Differential hRad17 expression by histologic subtype of ovarian cancer

Jennifer L Young2*, E Colin Koon3, Joseph Kwong4, William R Welch5, Michael G Muto1, Ross S Berkowitz1 and Samuel C Mok6

Author Affiliations

1 Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

2 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC, USA

3 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Baylor University Medical Center, Dallas, TX, USA

4 Centre for Translational Oncology, Institute of Cancer and the CR-UK Clinical Centre, Barts and the London Queen Mary's School of Medicine and Dentistry, London, UK

5 Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

6 Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

For all author emails, please log on.

Journal of Ovarian Research 2011, 4:6  doi:10.1186/1757-2215-4-6

Published: 30 March 2011

Abstract

Background

In the search for unique ovarian cancer biomarkers, ovarian specific cDNA microarray analysis identified hRad17, a cell cycle checkpoint protein, as over-expressed in ovarian cancer. The aim of this study was to validate this expression.

Methods

Immunohistochemistry was performed on 72 serous, 19 endometrioid, 10 clear cell, and 6 mucinous ovarian cancers, 9 benign ovarian tumors, and 6 normal ovarian tissue sections using an anti-hRad17 antibody. Western blot analysis and quantitative PCR were performed using cell lysates and total RNA prepared from 17 ovarian cancer cell lines and 6 normal ovarian epithelial cell cultures (HOSE).

Results

Antibody staining confirmed upregulation of hRad17 in 49.5% of ovarian cancer cases. Immunohistochemistry demonstrated that only 42% of serous and 47% of endometrioid subtypes showed overexpression compared to 80% of clear cell and 100% of mucinous cancers. Western blot confirmed overexpression of hRad17 in cancer cell lines compared to HOSE. Quantitative PCR demonstrated an upregulation of hRad17 RNA by 1.5-7 fold. hRad17 RNA expression differed by subtype.

Conclusions

hRad17 is over-expressed in ovarian cancer. This over-expression varies by subtype suggesting a role in the pathogenesis of these types. Functional studies are needed to determine the potential role of this protein in ovarian cancer.